These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 398207)

  • 1. Study on the immunological heterogeneity of Clostridium botulinum B type toxin.
    Rymkiewicz D; Sawicki J; Brühl A
    Arch Immunol Ther Exp (Warsz); 1979; 27(5):709-14. PubMed ID: 398207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Specific antitoxic therapy of botulism].
    Nikiforov VN; Nikiforov VV; Glukhikh OA; Tashpulatov ShA
    Sov Med; 1985; (10):46-50. PubMed ID: 3909448
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunological heterogeneity of Clostridium botulinum type B toxins.
    Shimizu T; Kondo H; Sakaguchi G
    Jpn J Med Sci Biol; 1974 Apr; 27(2):99-100. PubMed ID: 4134872
    [No Abstract]   [Full Text] [Related]  

  • 4. Outbreaks of type C botulism in waterfowl in Japan.
    Ono T; Azuma R; Kato T; Takeuchi S; Suto T
    Natl Inst Anim Health Q (Tokyo); 1982; 22(3):102-14. PubMed ID: 6761593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clostridium botulinum subtype Ba.
    Giménez DF
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 May; 257(1):68-72. PubMed ID: 6380157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Toxoids of botulinum toxin type G].
    Puig de Centorbi ON; Ciccarelli AS; Giménez DF
    Rev Argent Microbiol; 1980; 12(1):10-7. PubMed ID: 6755549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Identification of strain B 657 of Clostridium botulinum].
    Giménez DF; Giménez JA
    Rev Argent Microbiol; 1983; 15(1):51-5. PubMed ID: 6400761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
    Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
    Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First outbreak of botulism caused by Clostridium botulinum subtype Af].
    Fernández RA; Ciccarelli AS; Arenas GN; Giménez DF
    Rev Argent Microbiol; 1986; 18(1):29-31. PubMed ID: 3317514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.
    Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A
    Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemiluminescence immunosorbent assay (CLISA) and a possibility of the specific detection of soluble antigens of Clostridium botulinum type A.
    Ligieza J; Reiss J; Michalik M
    Arch Immunol Ther Exp (Warsz); 1994; 42(2):129-33. PubMed ID: 7503646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins.
    Torgeman A; Diamant E; Levin L; David AB; Epstein E; Girshengorn M; Mazor O; Rosenfeld R; Zichel R
    Vaccine; 2017 Dec; 35(52):7213-7216. PubMed ID: 29174678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral dosing of mice with Clostridium botulinum type C cultures and culture filtrates.
    Smith GR; Turner A
    Res Vet Sci; 1987 Jul; 43(1):134-5. PubMed ID: 3306852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic characterization of Clostridium botulinum strains isolated from infant botulism cases in Argentina.
    Sagua MD; Lúquez C; Barzola CP; Bianco MI; Fernández RA
    Rev Argent Microbiol; 2009; 41(3):141-7. PubMed ID: 19831311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of antitoxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin.
    Kozaki S; Miyazaki S; Sakaguchi G
    Infect Immun; 1977 Dec; 18(3):761-6. PubMed ID: 412790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induction and modulation of humoral immunity in mice by local nasal administration of botulinum toxoid type B].
    Hörmeyer E; Schultz A; Sailer J; Opitz G; Stünkel K; Petzoldt K
    Berl Munch Tierarztl Wochenschr; 1985 Jan; 98(1):16-9. PubMed ID: 3885940
    [No Abstract]   [Full Text] [Related]  

  • 17. [Value of the immunofluorescence test in the diagnosis of botulinum toxin poisoning in humans and animals. I. Identification of Clostridium botulinum type A, B, E, F and C in artificially infected industrial preserves by the indirect and direct immunofluorescence test].
    Anusz Z; Mierzejewski J; Skoczek A
    Przegl Epidemiol; 1973; 27(2):173-81. PubMed ID: 4578517
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinction between Clostridium botulinum type A strains associated with food-borne botulism and those with infant botulism in Japan in intraintestinal toxin production in infant mice and some other properties.
    Tabita K; Sakaguchi S; Kozaki S; Sakaguchi G
    FEMS Microbiol Lett; 1991 Apr; 63(2-3):251-6. PubMed ID: 1905658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targets in the search for preventive and therapeutic agents for botulism.
    Anniballi F; Lonati D; Fiore A; Auricchio B; De Medici D; Locatelli CA
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1075-86. PubMed ID: 25089560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Clostridium botulinum type A toxin by enzyme-linked immunosorbent assay with antibodies produced in immunologically tolerant animals.
    Dezfulian M; Bartlett JG
    J Clin Microbiol; 1984 May; 19(5):645-8. PubMed ID: 6376538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.